Wang Ya, Zhang Yujie, Wang Pengqian, Han Jing, Zhang Xiaojiang, Shi Feiyu, Zhang Zhe, Guo Gang, Wang Ruochen, Shao Dan, Wu Daocheng, She Junjun
Center for Gut Microbiome Research, Med-X Institute, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.
Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.
Small. 2024 Jul;20(29):e2310851. doi: 10.1002/smll.202310851. Epub 2024 Feb 9.
Inspired by the timely emergence of silkworm pupae from their cocoons, silkworm chrysalis-like probiotic composites (SCPCs) are developed for the comprehensive therapy of inflammatory bowel disease (IBD), in which probiotics are enveloped as the "pupa" in a sequential layering of silk sericin (SS), tannic acid (TA), and polydopamine, akin to the protective "cocoon". Compared to unwrapped probiotics, these composites not only demonstrate exceptional resistance to the harsh gastrointestinal environment and exhibit over 200 times greater intestinal colonization but also safeguard probiotics from the damage of IBD environment while enabling probiotics sustained release. The probiotics, in synergy with SS and TA, provide a multi-crossed comprehensive therapy for IBD that simultaneously addresses various pathological features of IBD, including intestinal barrier disruption, elevated pro-inflammatory cytokines, heightened oxidative stress, and disturbances in the intestinal microbiota. SCPCs exhibit remarkable outcomes, including a 9.7-fold reduction in intestinal permeability, an 8.9-fold decrease in IL-6 levels, and a 2.9-fold reduction in TNF-α levels compared to uncoated probiotics. Furthermore, SCPCs demonstrate an impressive 92.25% reactive oxygen species clearance rate, significantly enhance the richness of beneficial intestinal probiotics, and effectively diminish the abundance of pathogenic bacteria, indicating a substantial improvement in the overall therapeutic effect of IBD.
受蚕茧中蚕蛹适时羽化的启发,开发了蚕蛹样益生菌复合材料(SCPCs)用于炎症性肠病(IBD)的综合治疗,其中益生菌被包裹在丝胶蛋白(SS)、单宁酸(TA)和聚多巴胺的连续分层中,形成类似保护性“茧”的结构,作为“蛹”。与未包裹的益生菌相比,这些复合材料不仅对恶劣的胃肠道环境表现出卓越的抗性,肠道定植能力提高了200多倍,还能保护益生菌免受IBD环境的损害,同时实现益生菌的持续释放。益生菌与SS和TA协同作用,为IBD提供了一种多交叉的综合治疗方法,可同时解决IBD的各种病理特征,包括肠道屏障破坏、促炎细胞因子升高、氧化应激增强和肠道微生物群紊乱。与未包衣的益生菌相比,SCPCs表现出显著的效果,包括肠道通透性降低9.7倍、IL-6水平降低8.9倍、TNF-α水平降低2.9倍。此外,SCPCs表现出令人印象深刻的92.25%的活性氧清除率,显著提高了肠道有益益生菌的丰富度,并有效减少了病原菌的丰度,表明IBD的整体治疗效果有了实质性改善。